Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 3/2010

01.05.2010

KRAS Testing and Its Importance in Colorectal Cancer

verfasst von: Deepa T. Patil, Cory R. Fraser, Thomas P. Plesec

Erschienen in: Current Oncology Reports | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Cetuximab and panitumumab are monoclonal antibodies used in the treatment of metastatic colorectal cancer (mCRC) by selectively targeting the epidermal growth factor receptor (EGFR) axis. Studies have shown that mutations in codons 12/13 of exon 2 of the KRAS gene render these therapies ineffective. As a result, the National Comprehensive Cancer Network and American Society of Clinical Oncology recommend KRAS mutation testing in mCRC. Appropriate testing depends on the coordinated efforts of the entire treatment team, including the pathologist, who selects the tumor sample and testing platform as well as interprets and reports results. In addition to describing rationale and methodologies for KRAS mutation testing, the authors also summarize their algorithmic approach and elaborate the potential role of newer molecular biomarkers to predict anti-EGFR resistance in wild-type KRAS tumors.
Literatur
1.
Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225–249.CrossRefPubMed
2.
Engstrom PF: Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy 2008, 28:18S–22S.CrossRefPubMed
3.
Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20:1S–13S.PubMed
4.
Burgess AW, Cho HS, Eigenbrot C, et al.: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003, 12:541–552.CrossRefPubMed
5.
Spano JP, Fagard R, Soria JC, et al.: Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005, 16:189–194.CrossRefPubMed
6.
Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337–345.CrossRefPubMed
7.
Lockhart AC, Berlin JD: The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 2005, 32:52–60.CrossRefPubMed
8.
Goldstein NS, Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001, 92:1331–1346.CrossRefPubMed
9.
Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160–1174.CrossRefPubMed
10.
Edkins S, O’Meara S, Parker A, et al.: Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006, 5:928–932.PubMedCrossRef
11.
Saltz LB, Meropol NJ, Loehrer PJ Sr, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201–1208.CrossRefPubMed
12.
Lenz HJ, Van Cutsem E, Khambata-Ford S, et al.: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006, 24:4914–4921.CrossRefPubMed
13.
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11–22.CrossRefPubMed
14.
Lee GH: The Kras2 oncogene and mouse lung carcinogenesis. Med Mol Morphol 2008, 41:199–203.CrossRefPubMed
15.
Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295–308.CrossRefPubMed
16.
Samowitz WS, Curtin K, Schaffer D, et al.: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000, 9:1193–1197.PubMed
17.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67:2643–2648.CrossRefPubMed
18.
Di Fiore F, Blanchard F, Charbonnier F, et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166–1169.CrossRefPubMed
19.
• Di Nicolantonio F, Martini M, Molinari F, et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705–5712. BRAF mutations in KRAS wild-type tumors were inversely associated with response to therapy, with none of the BRAF V600E cases responding to anti-EGFR therapy versus 32% of KRAS wild-type/BRAF wild-type tumors.CrossRefPubMed
20.
Lievre A, Bachet JB, Boige V, et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374–379.CrossRefPubMed
21.
Souglakos J, Philips J, Wang R, et al.: Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009, 101:465–472.CrossRefPubMed
22.
Van Cutsem E, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408–1417.CrossRefPubMed
23.
•• Karapetis CS, Khambata-Ford S, Jonker DJ, et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757–1765. The effectiveness of cetuximab was significantly associated with KRAS mutation status compared to basic supportive care alone; significantly improved OS and PFS were noted in patients with wild-type KRAS tumors treated with cetuximab.CrossRefPubMed
24.
•• Bokemeyer C, Bondarenko I, Makhson A, et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663–671. This randomized controlled trial showed that addition of cetuximab to FOLFOX-4 for previously untreated patients with metastatic colorectal cancers led to significantly increased chance of response and lower risk of disease progression in patients with KRAS wild-type tumors.CrossRefPubMed
25.
• Amado RG, Wolf M, Peeters M, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626–1634. This subgroup analysis from a randomized phase 3 study demonstrated significant response rate and longer OS with panitumumab therapy in patients with wild-type KRAS tumors compared to mutant group.CrossRefPubMed
26.
Jimeno A, Messersmith WA, Hirsch FR, et al.: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009, 27:1130–1136.CrossRefPubMed
27.
Simi L, Pratesi N, Vignoli M, et al.: High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008, 130:247–253.CrossRefPubMed
28.
Ogino S, Kawasaki T, Brahmandam M, et al.: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005, 7:413–421.PubMed
29.
Packham D, Ward RL, Ap Lin V, et al.: Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn Mol Pathol 2009, 18:62–71.CrossRefPubMed
30.
• Weichert W, Schewe C, Lehmann A, et al.: KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2009, 12:35–42. This is a comparative analysis involving Sanger sequencing, array analysis, melt curve analysis, and pyrosequencing, including sensitivity, laboratory working time, and costs. All were equally effective for routine diagnostic KRAS mutation analysis.CrossRefPubMed
31.
Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990, 61:759–767.CrossRefPubMed
32.
Plesec TP, Hunt JL: KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009, 16:196–203.CrossRefPubMed
33.
Troncone G, Malapelle U, Cozzolino I, Palombini L: KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. Diagn Cytopathol 2010 Jan 4. doi:10.​1002/​dc.​21302.
34.
Solomon SB, Zakowski MF, Pao W, et al.: Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 2010, 194:266–269.CrossRefPubMed
35.
van Krieken JH, Jung A, Kirchner T, et al.: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2009, 454:233–235.CrossRef
36.
Allegra CJ, Jessup JM, Somerfield MR, et al.: American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091–2096.CrossRefPubMed
37.
Garnett MJ, Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 6:313–319.CrossRefPubMed
38.
Loupakis F, Ruzzo A, Cremolini C, et al.: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715–721.CrossRefPubMed
39.
Sartore-Bianchi A, Martini M, Molinari F, et al.: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851–1857.CrossRefPubMed
40.
Perrone F, Lampis A, Orsenigo M, et al.: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009, 20:84–90.CrossRefPubMed
41.
Moroni M, Veronese S, Benvenuti S, et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279–286.CrossRefPubMed
42.
Frattini M, Saletti P, Romagnani E, et al.: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139–1145.CrossRefPubMed
43.
Jhawer M, Goel S, Wilson AJ, et al.: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008, 68:1953–1961.CrossRefPubMed
44.
Razis E, Briasoulis E, Vrettou E, et al.: Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer 2008, 8:234.CrossRefPubMed
45.
Laurent-Puig P, Cayre A, Manceau G, et al.: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924–5930.CrossRefPubMed
46.
Italiano A, Follana P, Caroli FX, et al.: Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008, 15:649–654.CrossRefPubMed
47.
Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al.: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4:e7287.CrossRefPubMed
48.
Prenen H, De Schutter J, Jacobs B, et al.: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009, 15:3184–3188.CrossRefPubMed
49.
Lievre A, Bachet JB, Le Corre D, et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992–3995.CrossRefPubMed
Metadaten
Titel
KRAS Testing and Its Importance in Colorectal Cancer
verfasst von
Deepa T. Patil
Cory R. Fraser
Thomas P. Plesec
Publikationsdatum
01.05.2010
Verlag
Current Science Inc.
Erschienen in
Current Oncology Reports / Ausgabe 3/2010
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-010-0099-y

Weitere Artikel der Ausgabe 3/2010

Current Oncology Reports 3/2010 Zur Ausgabe

ReviewPaper

Current Management of Hepatocellular Cancer

ReviewPaper

Proton Beam Radiation Therapy for Head and Neck Malignancies

ReviewPaper

Current and Emerging Treatment Strategies for Anal Cancer

Clinical Trial Report

Prognostic and Predictive Factors in the Targeted Therapy Era: Filling in the Blanks

ReviewPaper

B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma

ReviewPaper

Renal Cell Carcinoma: Where Will the State-of-the-Art Lead Us?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise